Immunotherapy Strategies for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) represents a major global health challenge, with most patients presenting at advanced stages and limited curative options. Immunotherapy has emerged as a pivotal approach, leveraging the host immune system to recognise and eradicate malignant hepatocytes. Strategies include immune checkpoint blockade, which aims to reverse T-cell exhaustion by targeting inhibitory molecules such as programmed cell death protein-1 and cytotoxic T-lymphocyte-associated antigen-4. Combination regimens pairing checkpoint inhibitors with anti-angiogenic agents or kinase inhibitors seek to reprogramme the immunosuppressive microenvironment and enhance lymphocyte infiltration. Adoptive cell transfer—encompassing engineered T cells or natural killer cells—offers precision targeting of tumour-associated antigens, while therapeutic vaccines aim to boost antigen-specific immunity. A parallel focus on identifying and validating predictive biomarkers, including tumour mutational burden and immune gene signatures, aims to improve patient selection and monitor response. Advances in spatial and multi-omics profiling are refining our understanding of the tumour immune microenvironment, facilitating personalised immunotherapeutic regimens. Despite encouraging outcomes in subsets of patients, durable responses remain restricted, underscoring the need for rational combination designs, improved biomarkers and strategies to overcome local immune suppression within the liver milieu.

Research from Nature Portfolio

Recent preclinical models have generated genetically defined, immunocompetent murine systems that mirror human HCC subtypes. By integrating transcriptomic data from these models with patient-derived profiles, researchers have delineated four conserved molecular clusters. This stratification informed proof-of-principle trials, identifying cladribine in combination with standard-of-care agents as a subtype-specific immunomodulator with robust anti-tumour activity. In parallel, clinical evaluation of a kinase inhibitor with known immunomodulatory properties combined with an anti-PD-1 antibody in unresectable HCC demonstrated a one-year overall survival exceeding 80 per cent. Exploratory single-cell analyses of peripheral blood mononuclear cells revealed that long-term responders exhibited expanded proliferating CD8+ T-cell clones and markers of monocyte polarisation towards an M1 phenotype, shedding light on immune biomarkers predictive of durable benefit.

Immunotherapy Strategies for Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in immunotherapy strategies for hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint: A regulatory molecule on immune cells that modulates activation; blockade enhances anti-tumour T-cell function.

Tumour immune microenvironment: The network of immune, stromal and tumour cells within a cancer lesion that influences immune response.

Single-cell RNA sequencing: A method to profile gene expression at the level of individual cells, revealing cellular heterogeneity.

Radio-immunomics: An integrative approach combining radiographic imaging data with immunogenomic and molecular profiles to assess the tumour’s immune landscape.

Biomarker: A measurable indicator, such as a gene signature or protein level, used to predict or monitor therapeutic response.

References

1. Human-correlated genetic models identify precision therapy for liver cancer. Nature (2025).
2. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nature Medicine (2024).
3. Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment. Meta-Radiology (2024).
4. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (2020).